211 related articles for article (PubMed ID: 26297266)
1. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience.
Chavez JC; Dalia S; Sandoval-Sus J; Kharfan-Dabaja MA; Al-Ali N; Komrokji R; Padron E; Corrales-Yepez G; Rock-Klotz J; Pinilla-Ibarz J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S14-8. PubMed ID: 26297266
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
3. Genetics of lymphocytes influences the emergence of second cancer in chronic lymphocytic leukemia.
Bernués M; Durán MA; Puget G; Iglesias J; Galán P; Vercher FJ; Besalduch J; Rosell J
Anticancer Res; 2014 May; 34(5):2311-4. PubMed ID: 24778036
[TBL] [Abstract][Full Text] [Related]
4.
Habashy DM; Eissa DS; Aboelez MM
Turk J Haematol; 2018 Aug; 35(3):168-174. PubMed ID: 28884705
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Mauro FR; Galieni P; Tedeschi A; Laurenti L; Del Poeta G; Reda G; Motta M; Gozzetti A; Murru R; Caputo MD; Campanelli M; Frustaci AM; Innocenti I; Raponi S; Guarini A; Morabito F; Foà R; Gentile M
Am J Hematol; 2017 Jun; 92(6):529-535. PubMed ID: 28295527
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Robertson LE; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating MJ
Leukemia; 1994 Dec; 8(12):2047-51. PubMed ID: 7807993
[TBL] [Abstract][Full Text] [Related]
7. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Colović M; Suvajdžić N; Janković G; Tomin D; Colović N; Fekete MD; Palibrk V
Biomed Pharmacother; 2011 Aug; 65(5):319-21. PubMed ID: 21775097
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
[TBL] [Abstract][Full Text] [Related]
10. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
11. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
[TBL] [Abstract][Full Text] [Related]
12. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L
Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
[TBL] [Abstract][Full Text] [Related]
17. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death.
Kyasa MJ; Hazlett L; Parrish RS; Schichman SA; Zent CS
Leuk Lymphoma; 2004 Mar; 45(3):507-13. PubMed ID: 15160912
[TBL] [Abstract][Full Text] [Related]
18. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
Stanganelli C; Travella A; Bezares R; Slavutsky I
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of immunoglobulin variable heavy chain gene mutation status: long term follow-up in a series of chronic lymphocytic leukemia patients.
Panovska-Stavridis I; Cevreska L; Stojanovic A; Efremov D
Prilozi; 2006 Dec; 27(2):127-37. PubMed ID: 17211297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
